Avandia

Avandia (rosiglitazone maleate) is an nasal antidiabetic agent which acts primarily by increasing insulin sensitivity.
Avandia improves glycemic control trouble reducing circulating insulin levels.Rosiglitazone maleate is not chemically or functionally related to the sulfonylureas, the biguanides, or the alpha-glucosidase inhibitors.

What are the possible side effects of rosiglitazone (Avandia)?

Get emergency medical help if you have any of these betoken of an allergic reaction: hives; difficulty respiration; swelling of your face, lips, tongue, or throat.Stop using Avandia and call your doctor at former if you have any of these serious main effects:

feeling short of breath, even with mild exertion;
swelling or prompt load gain;
chest afflict or heavy sentient, afflict extenting to the arm or shoulder, sweating, general ill sentient;
nausea, stomach aggrieve, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or behold);
blurred vision;
increased thirst or hunger, urinating additional than usual; or pale skin, quiet bruising or bleeding, weakness.

Less grave side effects of Avandia may include:

sneezing, runny nose, cough or other signs of a cold; headache; gradual weight gain; mild diarrhea; or back well-being.
Prior to prescribing Avandia, refer to Indications and Usage for appropriate patient selection. incomparable prescribers enrolled in the Avandia-Rosiglitazone drug

Access Program can prescribe Avandia.
Avandia may be administered at a starting dose of 4 mg either as a single everyday dose or in 2 divided doses. For patients who respond inadequately following 8 to 12 weeks of treatment, as determined by reduction in fasting plasma glucose (FPG), the dose may be increased to 8 mg everyday. augment in the dose of Avandia should be accompanied by careful monitoring for hostile events related to fluid retention. Avandia may be taken with orwithout food.

The total daily dose of Avandia should not exceed 8 mg.

Patients receiving Avandia in combination with other hypoglycemic figures may be at venture for hypoglycemia, and a reduction in the dose of the concomitant figure may be necessary.

Overall, the types of adverse reactions notwithstandingout regard to causality repute when Avandia was used in combination notwithstanding a sulfonylurea or metformin were similar to those during monotherapy notwithstanding Avandia.

Events of anemia and edema nurse to be reported more frequently at higher doses, and were generally mild to moderate in severity and usually did not require discontinuation of steep with Avandia.

In clone-blind trials, anemia was repeat in 1.9% of diligent receiving Avandia as monotherapy compared to 0.7% on placebo, 0.6% on sulfonylureas, and 2.2% on metformin. story of anemia were greater in diligent gratification notwithstanding a combination of Avandia and metformin (7.1%) and notwithstanding a combination of Avandia and a sulfonylurea extra metformin (6.7%) compared to monotherapy notwithstanding Avandia or in combination notwithstanding a sulfonylurea (2.3%). Lower pre-treatment hemoglobin/hematocrit smooth in diligent wrap up in the metformin combination clinical trials may have contributed to the higher reporting rate of anemia in these trials.